Roll Call on Biogenerics
James K. Glassman and I published an article on biogenerics today in Roll Call. Continue Reading
James K. Glassman and I published an article on biogenerics today in Roll Call. Continue Reading
To provide some context to discussions on the term of protection for copyright and related rights, the following note sumarizes on the basic provisions in various multilateral copyright and related rights treaties, on the topics of minimum terms and formalities. … Continue Reading
Orphan Works are copyrighted works whose owners may be impossible to identify and locate. Undertanding the access and dissemination problems that these kind of works impose to society, Governments have began to explore ways to address the issue. Canada Canada… Continue Reading
On Saturday, KEI filed comments with the WHO EWG’s 2nd web based hearing. Our comments focused on the criteria for new proposals. Continue Reading
Press Release 15 Feb 07 FMI James Love +1.202.332.2670, cell +1.202.361.3040, james.love@keionline.org September 2, 2009 (See attachment for patent and health experts contact information) FTC ASKED TO INVESTIGATE GILEAD EFFORT TO CONTROL MARKET FOR AIDS DRUGS INGREDIENTS [Complaint available… Continue Reading
WHO website on the EWG NEWS: The EWG secretariat has released a draft evaluation framework, evaluation criteria and the inventory of financing proposals. The EWG is accepting public comments through the Second Web-based Public Hearing. Deadline: September 5 2009. KEI… Continue Reading
The web page for the Berkeley workshop on the Google Book Settlement is here. Much of the documentation about the settlement is available here. http://thepublicindex.org/
The agreed upon twitter hash tag seems to be: #gbsfia Continue Reading
According to this report from Pro Publica, the contract with a firm hired to make contracts public, is highly redacted.
Clay Johnson, the director of the Sunlight Labs [10] project at the Sunlight Foundation [11], called the level of redaction in the documents remarkable.
According to this August 15 report in the New York Times by David Kirkpatrick, drug companies pressed DLA Piper to fire Dick Armey, because Freedom Works, a group chaired by Dick Armey, was opposing the health reform legislation that PhRMA now backs. Continue Reading
In an August 14, 2009 article in the LA Times, Tom Hamburger provides yet another installment in the ongoing disclosures about a secret White House deal with PhRMA on pharmaceutical pricing.